Regeneron’s Injunction on Eylea Biosimilar Holds Up on Appeal

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron Pharmaceuticals Inc.‘s Eylea blockbuster eye-disease biologic.

In the latest turn in the case—which also involves major drugmakers including Mylan Pharmaceuticals Inc., Amgen Inc., Biocon Biologics Inc., and Samsung Bioepis Co.—a three-judge panel on Wednesday rejected Celltrion’s arguments that a West Virginia federla court lacked jurisdiction over it and that Regeneron wouldn’t suffer irreparable harm connected to its product launch.

The decision echoed the US Court of Appeals for the Federal Circuit’s January opinion upholding a similar injunction ...